Prelude Therapeutics Inc
PRLD
NASDAQ
Biotechnology
$5.55
USD
+0.19 (+3.54%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $431.68M
Volume 452.1K
Revenue
$22.42M
TTM
+220.3%
YoY
Gross Margin
100%
TTM
0.0%
YoY
Net Income
$-60.49M
TTM
+51.3%
YoY
Operating Cash Flow
$-33.26M
TTM
+69.3%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 0.0 | 6.5 | 5.6 | 4.6 | 5.7 |
YoY Growth | — | +116.7% | +41.0% | — | — |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 0.0 | 6.5 | 5.6 | 4.6 | 5.7 |
Selling, General & Administrative | 6.4 | 5.2 | 5.0 | 5.2 | 5.0 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 32.2 | 26.9 | 23.0 | 18.8 | 21.2 |
Operating Income | -32.2 | -20.4 | -17.3 | -14.2 | -15.5 |
EBITDA | -31.8 | -20.0 | -16.9 | -13.8 | -15.1 |
Other Income / Expense | 1.0 | 0.7 | 0.9 | 3.8 | 1.5 |
Total Other Income / Expense | 1.0 | 0.7 | 0.9 | 3.8 | 1.5 |
Income Before Income Taxes | -31.2 | -19.7 | -16.5 | -10.4 | -13.9 |
Income Taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Net Income | -31.2 | -19.7 | -16.5 | -10.4 | -13.9 |
Consolidated Net Income / Loss | -31.2 | -19.7 | -16.5 | -10.4 | -13.9 |
Net Income Attributable to Common Shareholders | -31.2 | -19.7 | -16.5 | -10.4 | -13.9 |
Basic EPS | -$0.41 | -$0.26 | -$0.21 | -$0.13 | -$0.14 |
Diluted EPS | -$0.41 | -$0.26 | -$0.21 | -$0.13 | -$0.14 |
Basic Shares Outstanding | 76.0M | 76.1M | 79.7M | 82.5M | 98.4M |
Diluted Shares Outstanding | 76.0M | 76.1M | 79.7M | 82.5M | 98.4M |